---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-054492"
form_type: "8-K"
ticker: null
cik: "0001444380"
company_name: "NEVRO CORP"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:28:17.251281+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nevro Q1 revenue $101.9M (+5.8%), net loss $35.8M; raises adjusted EBITDA guidance, promotes Christoforou to COO

## Summary
- Q1 2024 worldwide revenue $101.9M, up 5.8% YoY; net loss from operations $35.8M; adjusted EBITDA loss $9.6M.
- FY2024 revenue guidance reaffirmed at $435–445M; adjusted EBITDA guidance raised to loss $5M to profit $2M.
- Additional restructuring steps announced to accelerate profitability and strengthen operations.
- Christofer Christoforou promoted to newly created COO role; he has been with Nevro for eight years.
- SI joint business: over 220 physicians trained on Nevro1™, one of three SI joint products.

## SEC filing metadata
- accession: 0000950170-24-054492
- form_type: 8-K
- cik: 0001444380
- company_name: NEVRO CORP
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/0000950170-24-054492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/nvro-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-054492
- JSON: https://secwatch.observer/filing/0000950170-24-054492.json
- Plain text: https://secwatch.observer/filing/0000950170-24-054492.txt

## Key facts
- Earnings Releases
  NEVRO CORP updated its full-year 2024 guidance (raised).
  - Period: full-year 2024
  - Guidance: raised
  - Result: guidance update
  source text: reaffirming our revenue guidance of $435 million to $445 million for the full-year 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/0000950170-24-054492-index.htm
- Earnings Releases
  NEVRO CORP updated its full-year 2024 guidance (raised).
  - Period: full-year 2024
  - Guidance: raised
  - Result: guidance update
  source text: raising our adjusted EBITDA guidance to a range of a loss of $5 million to positive $2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/0000950170-24-054492-index.htm
- Earnings Releases
  NEVRO CORP reported first quarter 2024 results: revenue $101.9 million, net income loss of $35.8 million.
  - Period: first quarter 2024
  - Revenue: $101.9 million
  - Net income: loss of $35.8 million
  - Result: reported results
  source text: Worldwide revenue grew to $101.9 million, an increase of 5.8% as reported and 5.6% on a constant currency basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/0000950170-24-054492-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.